Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro

Shah, M., Gallipoli, P., Lyons, J., Holyoake, T. L. and Jorgensen, H. (2012) Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases, 48(3), pp. 199-201. (doi: 10.1016/j.bcmd.2012.01.005)

[img] Text
64199.pdf

294kB

Publisher's URL: http://dx.doi.org/10.1016/j.bcmd.2012.01.005


Item Type:Articles (Letter)
Additional Information:NOTICE: this is the author’s version of a work that was accepted for publication in Blood, Cells, Molecules and Diseases. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Blood, Cells, Molecules and Diseases, [48, 3, (2012)] doi:10.1016/j.bcmd.2012.01.005.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Gallipoli, Dr Paolo and Jorgensen, Dr Heather and Holyoake, Professor Tessa
Authors: Shah, M., Gallipoli, P., Lyons, J., Holyoake, T. L., and Jorgensen, H.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Blood Cells, Molecules, and Diseases
Publisher:Academic Press
ISSN:1079-9796
ISSN (Online):1096-0961
Copyright Holders:Copyright © 2012 Elsevier
First Published:First published in Blood, Cells, Molecules and Diseases 48(3):199-201
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
540351The relevance of autocrine growth factor activation to the survival and proliferation of primitive chronic myeloid leukaemia (CML) cells.Paolo GallipoliMedical Research Council (MRC)G1000288RI CANCER SCIENCES